Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.43 |
| ▸ | MAOA | P21397 | 6/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | CALML3 | P27482 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SDHA | P31040 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833888 | 0.91 | MAOA (0.38) | F10MAOAMAOBCALML3LMNA | |
| SCHEMBL5834573 | 0.90 | MAOA (0.47) | F10MAOAMAOBCALML3 | |
| SCHEMBL6762885 | 0.90 | MAOA (0.35) | F10MAOAMAOBCALML3LMNA | |
| SCHEMBL5834579 | 0.85 | MAOA (0.51) | F10MAOAMAOBCALML3LMNA | |
| SCHEMBL5833934 | 0.83 | MAOA (0.48) | F10MAOAMAOBCALML3LMNA | |
| SCHEMBL5833559 | 0.82 | F10 (0.42) | F10MAOAMAOBCALML3LMNA | |
| SCHEMBL7020886 | 0.82 | MAOA (0.53) | F10MAOAMAOBCALML3LMNA | |
| SCHEMBL5833333 | 0.80 | MAOA (0.45) | F10MAOAMAOBCALML3 | |
| SCHEMBL6765877 | 0.79 | MAOA (0.50) | F10MAOAMAOBCALML3LMNA | |
| SCHEMBL5833710 | 0.77 | MAOA (0.49) | F10MAOAMAOBCALML3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087629-B2 | Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams | ASTRAZENECA AB (SE) | 2006-08-08 | — | — | US | disclosed |
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | F10 1845/4885MAOA 652/4885MAOB 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.